Petrov M, Hadjieva N, Kantardjiev T, Velinov Tz, Bachvarova A
National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria.
Queen Joanna University Hospital, Sofia, Bulgaria.
Euro Surveill. 2005 Jun;10(6):7-8. doi: 10.2807/esm.10.06.00548-en.
We introduce Bulgarian Surveillance Tracking Antimicrobial Resistance (BulSTAR) and make the first report on surveillance data for 2003. This longitudinal surveillance programme monitors the isolation and antimicrobial susceptibility of all clinically significant microorganisms isolated from blood cultures, cerebrospinal fluid, upper and lower respiratory tract, urine and wound samples in the participating microbiology laboratories. Twenty eight public, 45 hospital and 6 private laboratories from all 28 counties of the Republic of Bulgaria participated in BulSTAR 2003. The total number of isolates from monitored sources during the surveillance period was 98 929. Seven microorganisms represented 72% of all isolated bacteria in BulSTAR 2003: Escherichia coli, Staphylococcus aureus, Proteus-Providencia-Morganella group, Klebsiella spp., Pseudomonas spp, Streptococcus pneumoniae and Streptococcus pyogenes. Generally the resistance of clinically significant Gram positive and Gram negative bacteria in Bulgaria was estimated to be at a medium level when compared with many other surveillance sources worldwide. A unique 32-year experiment on the population by treating all severe infections with an ampicillin/gentamicin combination resulted in twofold higher levels of resistance to amynoglycosides compared with other countries worldwide. This is due to the extremely conservative treatment schemes used in the former socialist countries, based on national directives and cheap domestic production of gentamicin and ampicillin. The forthcoming introduction of a computer network and improvements in detecting mistakes are expected to increase the sensitivity and the significance of BulSTAR surveillance system - an indispensable tool in the combat against increasing worldwide antibiotic resistance.
我们引入了保加利亚抗菌药物耐药性监测追踪系统(BulSTAR),并首次报告了2003年的监测数据。这个纵向监测项目监测参与的微生物实验室从血培养、脑脊液、上呼吸道和下呼吸道、尿液及伤口样本中分离出的所有具有临床意义的微生物的分离情况及抗菌药敏性。来自保加利亚共和国所有28个县的28家公共实验室、45家医院实验室和6家私人实验室参与了2003年的BulSTAR项目。监测期间从监测来源分离出的菌株总数为98929株。在2003年的BulSTAR项目中,7种微生物占所有分离细菌的72%:大肠杆菌、金黄色葡萄球菌、变形杆菌-普罗威登斯菌-摩根菌属、克雷伯菌属、假单胞菌属、肺炎链球菌和化脓性链球菌。总体而言,与世界上许多其他监测来源相比,保加利亚具有临床意义的革兰氏阳性和革兰氏阴性细菌的耐药性估计处于中等水平。一项针对全体人口的独特的32年实验,即用氨苄西林/庆大霉素联合治疗所有严重感染,导致对氨基糖苷类药物的耐药水平比世界其他国家高出两倍。这是由于前社会主义国家采用的极其保守的治疗方案,这些方案基于国家指令以及庆大霉素和氨苄西林的国内廉价生产。预计即将引入的计算机网络以及检测错误方面的改进将提高BulSTAR监测系统的敏感性和重要性,该系统是应对全球抗生素耐药性增加的不可或缺的工具。